As a consequence of the reduced earnings, BAML downgraded its price targets on Estia Health to $2.75 from $3.35, Regis to $3.70 from $4.30 and Japara to $1.90 from $2.30.
CLSA reduced its price target on Estia to $2.87 from $4.10, Japar's to $1.77 from $2.53 and Regis to $3.71 from $5.30, downgrading Estia to a "sell recommendation" from an "underperform", Japara to a "sell" recommendation an "outperform" and Regis also to a "sell" from a "buy" recommendation.
